Observation Study on Meibomian Gland Function after Comprehensive Facial Platelet-rich Plasma Therapy

Observation of function of meibomian gland after comprehensive partial platelet-rich plasma therapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600128838

Enrollment

Unknown

Registered

2026-07-27

Start date

2023-09-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction

Interventions

Standard treatment population:None

Platelet-rich plasma therapy for patients:None

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Have eye symptoms (dryness, foreign body sensation); 2.TBUT < 10s, the opening of upper and lower meibomian glands was evaluated, and cotton swabs were pressed against meibomian glands (yellow sticky or clear secretions were not easy to extrude). 3.Patients over 20 years old, male and female; 4.Patients with OSDI=13 or China Dry Eye Questionnaire =7;

Exclusion criteria

Exclusion criteria: 1.Patients with a history of eye trauma surgery; 2.Acute eye inflammation or infection; 3.Lactating or pregnant women;

Design outcomes

Primary

Measure	Time frame
Meibomian gland function score;Ocular Surface Disease Index;	—

Secondary

Measure	Time frame
breakup time of tear film;Corneal fluorescein sodium staining;	—

Countries

China

Contacts

Public ContactXuesong Mi

The First Affiliated Hospital, Jinan University

mxsong@163.com+86 20 3868 8397

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026